|
Sunshine Lake Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, production, and commercialization of drugs. The company develops small molecule drugs, biologics, and biosimilars, with a focus on therapeutic areas including infectious diseases, chronic diseases, and oncology. Its product portfolio includes approved medicines for influenza, hepatitis C, and diabetes, alongside a pipeline of candidates in various stages of clinical trials. The company operates integrated capabilities for drug discovery, manufacturing, and sales, utilizing AI-driven models to support its research processes. It serves markets in China, the United States, and Europe, and has established partnerships for the commercialization of specific drug candidates. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - General | Homepage hecpharm.com |
| Sector Healthcare | IR page hecpharm.com/investor_relations.html | |
|
Tags
innovative drugs, biosimilars, generic drugs, infectious diseases, oncology, diabetes, ai drug discovery, cdmo services, small molecule drugs, biologics, Dongguan HEC Medicine, Dongguan HEC Biopharmaceutical, Guangdong HEC Biopharmaceutical, Shenzhen HEC Industrial, Guangdong HEC Technology Holding Co. Ltd., Yichang HEC Medicine, Dongguan HEC Research, Dongguan HEC Medical, HEC CJ Pharm, Guangzhou Yangzhiguang Trading Co. Ltd., Ruyuan Yao Autonomous County Taidong Pharmaceutical Co. Ltd., Yidu Tang Junyi Health Industry Development Co. Ltd., Yidu Tang Juntao Pharmaceutical Technology Co. Ltd., Dongguan HEC Gaoneng Medical Equipment Co. Ltd., Linzhi HEC Pharmaceutical Research, Dongguan HEC Industrial Development Co. Ltd., Yichang HEC Research, Guangdong Southern China Advanced Pharmaceutical Co. Ltd., Dongyang HEC Industrial Development Co. Ltd., Yidu HEC Industrial, HEC-SynAI, HEC169584, HEC88473, HECN30227, Olopatadine, Natanvir, Ecozibuvir, Fingolimod, Emtravirine, Ifeenikone, Azithromycin, Oseltamivir, Insulin, Glargine, Aspart, Aspart 30
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 11.77B |
| Market cap (USD) | $ 1.5B |
| P/E | 59.02 |
| PEG | — |
| P/BV | 3.36 |
| P/S | 2.08 |
| P/OCF | 8.66 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.13% |
| Returns | |
|---|---|
| ROE | 6.2% |
| ROI | 3.1% |
| ROIC | 7.5% |
| Profit margin | 5.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | 105.3% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 41.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Sunshine Lake Pharma Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.11% | 30,500 | $ 141.867K | Nov 16, 2026 |
| AVEM | 0.01% | 725,105 | $ 3.373M | Nov 16, 2026 |
| DFEM | 0.01% | 147,572 | $ 711.839K | Nov 12, 2026 |
| DFSE | 0.00% | 3,532 | $ 17.037K | Nov 12, 2026 |
| DFAX | 0.00% | 62,658 | $ 302.241K | Nov 12, 2026 |
| DFAE | 0.00% | 39,669 | $ 191.35K | Nov 12, 2026 |
| AVES | 0.00% | 10,218 | $ 47.528K | Nov 16, 2026 |
| AVSE | 0.00% | 52 | $ 241.87 | Nov 16, 2026 |




粤ICP备2021116245号-1


